Science Explorer Back to mapMap
Discussion
Topic · Cardiology and Cardiovascular Medicine

Atrial Fibrillation Management and Outcomes

Atrial Fibrillation Management and Outcomes is a research topic within Cardiology and Cardiovascular Medicine. Science Explorer counts 73k research works in it since 1950. 10.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the management, treatment, and risk assessment of atrial fibrillation (AF). It covers topics such as anticoagulant therapy, catheter ablation, stroke prevention, risk stratification, and guidelines for managing AF. The papers also compare different medications such as warfarin, rivaroxaban, and dabigatran for the treatment of AF.

  • Atrial Fibrillation
  • Anticoagulant Therapy
  • Catheter Ablation
  • Stroke Prevention
  • Risk Stratification
  • Guidelines
  • Thromboembolism
  • Warfarin
  • Rivaroxaban
  • Dabigatran
Research works
73k
fractional, since 1950
In the world top 10%
7.3k
per year above
Top-10% rate
10.0%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+8%
the tick is no change
Largest producer
United States
37% of the 10 largest, 2022-now
Atrial Fibrillation Management and Outcomes

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Atrial Fibrillation Management and Outcomes research?

By volume, the United States and China publish the most (4.5k and 2.1k works in 2022-now).

By volume, 2022-now

  1. 1 United States 4.5k works
  2. 2 China 2.1k works
  3. 3 Japan 1.2k works
  4. 4 Italy 905 works
  5. 5 Germany 882 works
  6. 6 United Kingdom 812 works
  7. 7 Spain 596 works
  8. 8 France 439 works
  9. 9 Canada 417 works
  10. 10 South Korea 409 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 36.8%China: 16.9%Japan: 9.8%Italy: 7.4%6 others listed: 29.1%37%largest
United States4,504 · 36.8%China2,071 · 16.9%Japan1,198 · 9.8%Italy905 · 7.4%6 others listed3,556 · 29.1%

Shares of the rows listed above, not of the whole node.

Which institutions lead Atrial Fibrillation Management and Outcomes research?

By volume in 2022-now, Harvard University publishes the most Atrial Fibrillation Management and Outcomes research, followed by Mayo Clinic and Capital Medical University.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 204 works
  2. 2 Mayo ClinicUnited States 172 works
  3. 3 Capital Medical UniversityChina 136 works
  4. 4 University of LiverpoolUnited Kingdom 122 works
  5. 5 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 97 works
  6. 6 Cleveland ClinicUnited States 83 works
  7. 7 Shanghai Jiao Tong UniversityChina 81 works
  8. 8 University of CopenhagenDenmark 76 works
  9. 9 The University of SydneyAustralia 69 works
  10. 10 Yonsei UniversitySouth Korea 68 works

Who are the leading researchers in Atrial Fibrillation Management and Outcomes?

The most-cited researchers publishing on Atrial Fibrillation Management and Outcomes include Douglas G. Altman, George Davey Smith and Julian P. T. Higgins.

  1. 1 Douglas G. Altman United Kingdom 862k citations
  2. 2 George Davey Smith United Kingdom 435k citations
  3. 3 Julian P. T. Higgins United Kingdom 390k citations
  4. 4 John J.V. McMurray United Kingdom 349k citations
  5. 5 Hermann Brenner Germany 343k citations
  6. 6 Cyrus Cooper United Kingdom 342k citations
  7. 7 Emelia J. Benjamin United States 341k citations
  8. 8 Valery L. Feigin New Zealand 341k citations
  9. 9 Jun Wang China 340k citations
  10. 10 Stephan Windecker Switzerland 338k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Atrial Fibrillation Management and Outcomes?

The most cited paper in Atrial Fibrillation Management and Outcomes is "Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis" (Qinghua Zhang, Chao Wang, Maoyong Zheng et al., 2014), with 11,556 citations. Next come "Dabigatran versus Warfarin in Patients with Atrial Fibrillation" (11,272) and "2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)" (10,145).

Most cited papers
#PaperReleasedCitations
1 Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis Qinghua Zhang, Chao Wang, Maoyong Zheng et al. · Cerebrovascular Diseases ReviewOpen access 24 Dec 2014 11,556
2 Dabigatran versus Warfarin in Patients with Atrial Fibrillation Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al. · New England Journal of Medicine Open access 30 Aug 2009 11,272
3 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Gerhard Hindricks et al. · European Heart Journal Open access154 authors 17 Jul 2020 10,145
4 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Borja Ibáñez et al. · European Heart Journal Open access127 authors 26 Aug 2017 9,924
5 Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine Open access 10 Aug 2011 9,484
All 96 most cited papers, with filters and sorting

Where is Atrial Fibrillation Management and Outcomes research done?

The largest centres of Atrial Fibrillation Management and Outcomes research in 2022-now are Beijing (China), Tokyo (Japan), Seoul (South Korea) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Bad Oeynhausen.

Largest cities, 2022-now

  1. 1 BeijingChina 376 works
  2. 2 TokyoJapan 281 works
  3. 3 SeoulSouth Korea 241 works
  4. 4 New YorkUnited States 227 works
  5. 5 LondonUnited Kingdom 227 works
  6. 6 BostonUnited States 194 works
  7. 7 MadridSpain 189 works
  8. 8 ShanghaiChina 178 works
  9. 9 ClevelandUnited States 151 works
  10. 10 MoscowRussia 150 works

Where it is the local speciality

  1. Bad OeynhausenDE · 22.8 works57×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Atrial Fibrillation Management and Outcomes than the world average.

See Atrial Fibrillation Management and Outcomes on the map

Where is the best place to study Atrial Fibrillation Management and Outcomes?

Among universities, judged by research, University of Liverpool, Harvard University and University of Bern score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 19.25%fractional works in this field (log) →share of work in the world top 10% →Liverpool John Moore…University of BernUniversity of Liverp…Harvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1University of LiverpoolUnited Kingdom 76.618.6%14.0×122 +10.6%
2Harvard UniversityUnited States 76.016.5%4.2×204 +12.3%
3University of BernSwitzerland 74.921.8%7.2×60 +68.8%
4Liverpool John Moores UniversityUnited Kingdom 74.226.0%9.4×21 +1632.7%
5Maastricht UniversityNetherlands 66.416.0%10.3×62 +8.3%
6University of CopenhagenDenmark 66.013.0%5.3×76 +17.6%
7Vrije Universiteit BrusselBelgium 65.223.5%6.7×29 +22.5%
8University of BaselSwitzerland 62.015.3%7.5×43 +48.8%
9Universität HamburgGermany 61.919.4%4.0×45 +36.4%
10Aalborg UniversityDenmark 61.022.4%4.8×41 -26.3%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Atrial Fibrillation Management and Outcomes, country by country

Is Atrial Fibrillation Management and Outcomes research growing?

Output in 2022-2025 was 8% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Atrial Fibrillation Management and Outcomes.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Atrial Fibrillation Management and Outcomes as a percentage of every work published that year, 0.069% in 2024.

still counting0.050%0.10%Atrial Fibrillation Management and Outcomes0.072% in 202519801990200020102020

Fractional works of Atrial Fibrillation Management and Outcomes over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Atrial Fibrillation Management and Outcomes9.9% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Atrial Fibrillation Management and Outcomes. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.